BMEDiShares Health Innovation Active ETF
Seeks to maximize total return.
By BlackRock · Launched 2020
Annual Cost
0.55%
#3,020 of 6,040 · average
Fund Size
$14M
#4,807 of 6,040 · small
Return (1Y)
+30.6%
Track Record
5 years
#2,171 of 6,040 · seasoned
Performance
Total-return NAV · USDGrowth of $10,000
$12,909+29.1%
Total-return NAV, USD. Net of fund fees, before tax.
What's inside
How Beacon categorizes this fundAsset class
EquityRegion
North americaCap
Multi cap
Strategy
Active selection
Sector
Health careFocus
Biotech & Genomics
Holdings
By weightConcentration
Top 10 holdings = 44.0% of fundmoderately concentrated
Johnson & Johnson
7.9%
Gilead Sciences Inc
5.4%
Edwards Lifesciences Corp
4.7%
Amgen Inc
4.6%
BLACKROCK CASH FUNDS TREASURY SL AGENCY SHARES
4.4%
Merck & Co Inc
3.9%
Biogen Inc
3.6%
Wuxi Biologics Cayman Inc
3.2%
Waters Corp
3.2%
Mettler-Toledo International Inc
3.1%
Asset allocation
Stocks
99.0%
Cash
1.1%
By sector
Healthcare
100.0%
Risk profile
Last 12 months · Sharpe & Sortino need 3+ yearsVolatility (1Y)
17.3%Moderate
Year-on-year price swings
Max drawdown
-36.5%Severe
Worst peak-to-trough loss
Sharpe (3Y)
0.59Decent risk-adjusted returns
Sortino (3Y)
0.86Moderate downside risk
Listing
- Exchange
- NYSE Arca
Full fund details
- Objective
- Seeks to maximize total return.
- Strategy
- Actively manages investments primarily in equity securities of mid- and small-capitalization companies in the health sciences group of industries, including healthcare providers and biotechnology firms. The Fund may invest globally and utilize derivatives for risk management and income enhancement.
- Inception date
- September 29, 2020
- Fund family
- BlackRock
Similar funds
Same asset class, closest by strategy & exposureNext steps
Save BMED to compare it with other funds, or start building a portfolio.
Data updated on 2026-09-18